By Fineline Cube Ocumension Therapeutics (HKG: 1477) announced that the new drug application (NDA) for its key drug candidate OT‑301 (NCX 470, bimatoprost grenod) — a treatment to lower intraocular pressure (IOP) in patients with open‑angle glaucoma or ocular hypertension — has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), marking a decisive step toward potential approval of a first‑in‑class ophthalmology therapy in Greater China.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA — Center for Drug Evaluation (China) |
| Application Type | New drug application (NDA) — accepted |
| Product | OT‑301 (NCX 470, bimatoprost grenod), ophthalmic solution, 0.1 % |
| Indication | Lowering of IOP in patients with open‑angle glaucoma or ocular hypertension |
| NDA Basis | Two Phase III trials: Mont Blanc and Denali |
| Announcement Date | 11 Sep 2026 |
| Next Steps | CDE technical review; potential approval timeline not disclosed |
Drug Profile & Mechanism of Action
- Molecule: OT‑301 (bimatoprost grenod) — a novel nitric oxide (NO)‑donating prostaglandin analog under joint development by Nicox S.A. and Ocumension.
- Dual Mechanism: Designed to release both bimatoprost — a prostaglandin analog already approved by the U.S. FDA — and nitric oxide (NO), delivering two complementary IOP‑lowering pathways in a single topical therapy.
- License Structure: December 2018 — Ocumension obtained an exclusive license from Nicox to develop, make, have made, import, export and sell OT‑301 in Greater China; March 2020 — exclusive rights extended to Korea and 12 Southeast Asian countries.
- Strategic Position: OT‑301 is a key drug candidate in Ocumension’s ophthalmology portfolio, targeting one of the largest chronic eye‑disease markets in Asia.
Clinical Evidence – Two Phase III Trials
| Trial | Design / Population | Primary Endpoint Outcome |
|---|---|---|
| Mont Blanc | Completed successfully in the United States and China (2022) | Robust efficacy and safety demonstrated |
| Denali | OT‑301 ophthalmic solution, 0.1 % versus latanoprost 0.005 % (current standard of care) in open‑angle glaucoma / ocular hypertension | Achieved primary endpoint of non‑inferiority |
The NDA is supported by the Mont Blanc trial, successfully completed in the U.S. and China in 2022, in which the primary endpoint showed robust efficacy and safety, and the Denali trial, a head‑to‑head study versus the current standard of care latanoprost ophthalmic solution, 0.005 %, which achieved its primary endpoint of non‑inferiority in lowering IOP. Detailed efficacy values, sample sizes and safety data were not disclosed in the announcement.
Market Impact & Outlook
- Large Chronic‑Disease Opportunity: Open‑angle glaucoma and ocular hypertension affect a substantial and ageing patient population in China, where long‑term IOP control remains the only proven strategy to slow vision loss — supporting a sizeable chronic‑therapy market for topical agents.
- Differentiated Dual Mechanism: If approved, OT‑301’s combined prostaglandin + NO‑donation mechanism would offer a novel option versus existing monotherapies, with potential advantages in IOP‑lowering breadth.
- Non‑Inferiority vs Standard of Care: The Denali result positions OT‑301 as at least on par with latanoprost, the most widely prescribed IOP‑lowering agent — a commercially meaningful benchmark for formulary and prescriber acceptance.
- Regional Expansion Pathway: With exclusive rights spanning Greater China, Korea and 12 Southeast Asian countries, Ocumension can pursue a coordinated multi‑market launch strategy following a potential China approval; pricing, launch timing and further filing plans were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the CDE review timeline, potential approval and commercialization of OT‑301 (NCX 470, bimatoprost grenod). Actual results may differ materially due to risks including regulatory review outcomes, clinical and manufacturing requirements, market adoption and competitive dynamics. NDA acceptance does not guarantee approval.-Fineline Info & Tech